Literature DB >> 21922357

Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year.

Masayasu Hara1, Mikinori Sato, Hiroki Takahashi, Satoru Takayama, Hiromitsu Takeyama.   

Abstract

PURPOSE: The aim of the present study was to determine the accuracy of yearly postoperative monitoring of serum tumor markers to either detect or rule out recurrence in colorectal cancer patients.
METHODS: A total of 127 colorectal cancer patients who underwent curative surgery were enrolled. The serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels were assayed, and radiological examinations were performed routinely for 5 years after surgery or until recurrence was detected. Yearly recurrence rates (number of recurrences/number of patients assessed in a given year), sensitivities, specificities, and likelihood ratios were calculated. Post-test probabilities were calculated from these values.
RESULTS: Recurrences tended to show almost the same frequencies in the first and second year after surgery (20 of 127 patients and 18 of 107 patients, respectively). However, the post-test probability of recurrence in patients with positive and negative serum CEA levels was significantly lower in the second year than in the first year (test positive: 40.0% and 76.0%; test negative: 9.3% and 0.5%, respectively).
CONCLUSIONS: Measuring CEA can help to identify patients likely to demonstrate recurrence with high accuracy only within the first year after surgery. Another examination, such as imaging, is therefore necessary for monitoring patients at 2 or more years after surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21922357     DOI: 10.1007/s00595-010-4519-2

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  25 in total

1.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer.

Authors:  K M Tveit
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

2.  Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Authors:  Luis C Fernandes; Su B Kim; Sarhan S Saad; Delcio Matos
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

3.  Surveillance after colorectal cancer surgery.

Authors:  L De Salvo; F Razzetta; A Arezzo; U Tassone; G Bogliolo; D Bruzzone; F Mattioli
Journal:  Eur J Surg Oncol       Date:  1997-12       Impact factor: 4.424

4.  Serum CEA monitoring in the follow-up of colorectal cancer patients with negative preoperative serum CEA.

Authors:  G Mariani; M Carmellini; F Bonaguidi; M A Benelli; M G Toni
Journal:  Eur J Cancer       Date:  1980-08       Impact factor: 9.162

5.  Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis.

Authors:  Hartwig Körner; Kjetil Söreide; Pål Johan Stokkeland; Jon Arne Söreide
Journal:  Ann Surg Oncol       Date:  2007-02       Impact factor: 5.344

6.  Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.

Authors:  Christopher E Desch; Al B Benson; Mark R Somerfield; Patrick J Flynn; Carol Krause; Charles L Loprinzi; Bruce D Minsky; David G Pfister; Katherine S Virgo; Nicholas J Petrelli
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

7.  CA19-9 as a predictor of recurrence in patients with colorectal cancer.

Authors:  T Nakayama; M Watanabe; T Teramoto; M Kitajima
Journal:  J Surg Oncol       Date:  1997-12       Impact factor: 3.454

8.  Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years.

Authors:  Sotaro Sadahiro; Toshiyuki Suzuki; Kenji Ishikawa; Tomoki Nakamura; Yoichi Tanaka; Takahisa Masuda; Sayuri Mukoyama; Seiei Yasuda; Tomoo Tajima; Hiroyasu Makuuchi; Chieko Murayama
Journal:  Hepatogastroenterology       Date:  2003 Sep-Oct

Review 9.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

Authors:  M J Duffy; A van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; R Lamerz; P Peltomaki; C Sturgeon; O Topolcan
Journal:  Eur J Cancer       Date:  2007-05-18       Impact factor: 9.162

10.  The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer.

Authors:  J L McCall; R B Black; C A Rich; J R Harvey; R A Baker; J M Watts; J Toouli
Journal:  Dis Colon Rectum       Date:  1994-09       Impact factor: 4.585

View more
  5 in total

1.  MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model.

Authors:  Sang-Yeul Lee; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Serum GROβ: a potential tumor-associated biomarker for colorectal cancer.

Authors:  Zhaoxu Zheng; Min Zheng; Jianjun Bi; Qiang Feng; Zhigang Yue; Yanqiu Zhou; Wanning Hu; Haizeng Zhang; Hongjun Gao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Colon cancer-specific antigen-2 may be used as a detecting and prognostic marker in colorectal cancer: a preliminary observation.

Authors:  Gang Xue; Xiaojuan Wang; Yong Yang; Degui Liu; Ying Cheng; Jun Zhou; Yongkuan Cao
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 4.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

5.  Diagnostic Accuracy of Elevated Serum Carcinoembryonic Antigen for Recurrence in Postoperative Stage II Colorectal Cancer Patients: Comparison With Stage III.

Authors:  Ho Seung Kim; Min Ro Lee
Journal:  Ann Coloproctol       Date:  2013-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.